Bionomics

  • Bionomics Announces Trial Results for Antidepressant Drug

    Bionomics has announced the final results of its Phase Ia clinical trial of BNC210. The primary objectives of the trial, to evaluate the safety, tolerability and the pharmacokinetics of the drug were met when stage one trial results were reported on …

    Bionomics | 11 March 2010

  • Bionomics to Conduct Phase II Trial For Cancer Treatment in Australia

    Bionomics has announced its plans to conduct a Phase II clinical trial of its BNC105 anti-cancer drug on 60 mesothelioma patients, at up to twelve centers in Australia. The company has contracted the Australasian Lung Cancer Trials Group (ALTG) a…

    Bionomics | 16 December 2009

  • Bionomics to Develop Cancer Drug Target BNO69

    Australia-based drug discovery company, Bionomics Limited has announced that its proprietary cancer drug target, BNO69 will progress to the next stage of development following the CRC for Cancer Therapeutics’ decision to support this program. The C…

    Bionomics | 01 September 2007